Announcements
Bonnie Cullison has been appointed as the new chair of the Maryland Prescription Drug Affordability Board, effective August 7, 2026. Please see a message from Chair Cullison:
"I am honored by the opportunity from the House Speaker and Senate President to continue my public service as chair of the Prescription Drug Affordability Board. Under the previous leadership of chair Van Mitchell, the Board has done important work to build a rigorous, transparent, comprehensive, and strategic approach to understanding how rising pharmaceutical costs affect overall health care costs for government entities. That work has already helped identify responsible options to constrain public spending, including limits on how much government entities may pay for certain high-cost drugs. At its core, this is responsible budgeting with a clear public purpose: helping Marylanders benefit from more affordable health care and, ultimately, lower insurance premiums. I look forward to working with Board members and diverse stakeholders across the state as we continue this important effort."
- Upcoming Prescription Drug Affordability Board Stakeholder Council Meeting
- Date: Monday, August 24, 2026 at 2:00 PM
- View meeting and registration information
What We Do
Cost Reviews
The Cost Review Study Process is the procedure by which the Board studies—that is, examines and analyzes—selected drugs to inform future policy recommendations and actions.
Public Meetings
Board Meetings and Stakeholder Council Meetings are both open to the public to provide transparency into the cost review process and the work of the PDAB.
Fee Assessments
PDAB assesses manufacturers, distributors, carriers and pharmacy benefits managers an annual assessment to fund the Prescription Drug Affordability Fund.
Contact us
Please reach out for any questions about fee assessments, public comments or general inquiries. For news and updates, join our mailing list.